Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 3/20 | 0.32 |
| ▸ | CDK1 | P06493 | 3/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1129156 | 0.86 | AURKA (0.38) | CHEK1AURKACCR4POLBOPRK1 | |
| SCHEMBL8466511 | 0.83 | CHEK1 (0.36) | CHEK1AURKACCR4CDK1 | |
| SCHEMBL18588897 | 0.83 | ALDH1A1 (0.31) | CCR4 | |
| SCHEMBL13717511 | 0.80 | PIK3CD (0.37) | EGFRSRCABL1 | |
| SCHEMBL4923299 | 0.79 | — | — | |
| SCHEMBL1128452 | 0.77 | CHEK1 (0.47) | CHEK1AURKACCR4EGFRCDK1 | |
| SCHEMBL9918632 | 0.76 | CCR4 (0.50) | CHEK1AURKACCR4POLBEGFR | |
| SCHEMBL1128551 | 0.76 | CHEK1 (0.43) | CHEK1AURKACCR4EGFRCDK1 | |
| SCHEMBL4931635 | 0.76 | AURKA (0.39) | CHEK1AURKACCR4EGFRCDK1 | |
| SCHEMBL15559040 | 0.75 | CHEK1 (0.40) | CHEK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2566866-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES USEFUL AS PKC-THETA INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-8076338-B2 | Such as 6-(4-phenylpiperazin-1-yl)-9H-purine; cell proliferation/differentiation | EXELIXIS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| EP-1750727-A2 | KINASE MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005117909-A2 | KINASE MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172379-A1 | 4 SUBSTITUTED PYRAZOLOPYRIMIDINES | MAP4K5, MAP4K4, MAP4K2 | CHEK1 247/4885AURKA 222/4885CCR4 2218/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | CHEK1 4647/4885AURKA 4802/4885CCR4 2369/4885 |
| US-20080076774-A1 | Kinase Modulators and Methods of Use | AKT3, RPS6KA3, CDK3 | CHEK1 208/4885AURKA 859/4885CCR4 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.